<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30278449</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1421-9778</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>50</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology</Title>                <ISOAbbreviation>Cell. Physiol. Biochem.</ISOAbbreviation>            </Journal>            <ArticleTitle>miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.</ArticleTitle>            <Pagination>                <MedlinePgn>136-149</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1159/000493964</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND/AIMS" NlmCategory="OBJECTIVE">Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen. Altered expression and functions of microRNAs (miRNAs) have been reportedly associated with tamoxifen resistance. Thus, it is necessary to further elucidate the function and mechanism of miRNAs in tamoxifen resistance.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Tamoxifen sensitivity was validated by using Cell Counting Kit-8 in tamoxifen-sensitive breast cancer cells (MCF-7, T47D) and tamoxifen-resistant cells (MCF-7/TAM, T47D/ TAM). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect the expression level of miR-449a in tamoxifen-sensitive/-resistant cells and patient serums. Dual-luciferase assay was used to identify the binding of miR-449a and predicted gene ADAM22. The expression level of ADAM22 was determined by qRT-PCR and western blotting in miR-449a +/- breast cancer cells. Subsequently, rescue experiments were carried out to identify the function of ADAM22 in miR-449a-reduced tamoxifen resistance. Finally, Gene ontology (GO) and Protein-protein interaction analyses were performed to evaluate the potential mechanisms of ADAM22 in regulating tamoxifen resistance.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">MiR-449a levels were downregulated significantly in tamoxifen-resistant breast cancer cells when compared with their parental cells, as well as in clinical breast cancer serum samples. Overexpression of miR-449a re-sensitized the tamoxifen-resistant breast cancer cells, while inhibition of miR-449a conferred tamoxifen resistance in parental cells. Luciferase assay identified ADAM22 as a direct target gene of miR-449a. Additionally, silencing of ADAM22 could reverse tamoxifen resistance induced by miR-449a inhibition in ER-positive breast cancer cells. GO analysis results showed ADAM22 was mainly enriched in the biological processes of cell adhesion, cell differentiation, gliogenesis and so on. Protein-protein interaction analyses appeared that ADAM22 might regulate tamoxifen resistance through PPARG, LGI1, KRAS and LYN.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Decreased miR-449a causes the upregulation of ADAM22, which induces tamoxifen resistance of breast cancer cells. These results suggest that miR-449a, functioning by targeting ADAM22, contributes to the mechanisms underlying breast cancer endocrine resistance, which may provide a potential therapeutic strategy in ER-positive breast cancers.</AbstractText>                <CopyrightInformation>Â© 2018 The Author(s). Published by S. Karger AG, Basel.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Mingjie</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jin</LastName>                    <ForeName>Jiao</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Clinical Laboratory, Obstetrics and Gynecology Hospital Affiliated to Nanjing Medical University (Nanjing Maternity and Child Health Hospital), Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lu</LastName>                    <ForeName>Xiyi</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Tongpeng</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jin</LastName>                    <ForeName>Shidai</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>02</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Cell Physiol Biochem</MedlineTA>            <NlmUniqueID>9113221</NlmUniqueID>            <ISSNLinking>1015-8987</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D020413">3' Untranslated Regions</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000070416">Antagomirs</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D018931">Antineoplastic Agents, Hormonal</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C116499">LGI1 protein, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="C544530">MIRN449 microRNA, human</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047495">PPAR gamma</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011506">Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>094ZI81Y45</RegistryNumber>                <NameOfSubstance UI="D013629">Tamoxifen</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.24.-</RegistryNumber>                <NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>EC 3.4.24.-</RegistryNumber>                <NameOfSubstance UI="C498474">ADAM22 protein, human</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D020413" MajorTopicYN="N">3' Untranslated Regions</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000070416" MajorTopicYN="N">Antagomirs</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018931" MajorTopicYN="N">Antineoplastic Agents, Hormonal</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015536" MajorTopicYN="N">Down-Regulation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009419" MajorTopicYN="N">Nerve Tissue Proteins</DescriptorName>                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047495" MajorTopicYN="N">PPAR gamma</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034622" MajorTopicYN="N">RNA Interference</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D034741" MajorTopicYN="N">RNA, Small Interfering</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016415" MajorTopicYN="N">Sequence Alignment</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013629" MajorTopicYN="N">Tamoxifen</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">ADAM22</Keyword>            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Estrogen receptor</Keyword>            <Keyword MajorTopicYN="N">Tamoxifen resistance</Keyword>            <Keyword MajorTopicYN="N">miR-449a</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>01</Month>                <Day>11</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>6</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>3</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30278449</ArticleId>            <ArticleId IdType="pii">000493964</ArticleId>            <ArticleId IdType="doi">10.1159/000493964</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>